MedTrace Logo

Cervical Preparation With Mifepristone Prior to Osmotic Dilators

NCT03714880 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 44

Last updated 2022-06-08

Study results available
· View outcomes & findings →

Summary

The investigators plan to study the role of mifepristone prior to the placement of cervical osmotic dilators to evaluate if the medication helps increase the number of dilators. This may help improve safety of dilation and evacuation (D\&E) procedures.

Conditions

  • Second Trimester Abortion

Interventions

DRUG

Mifepristone 200 MG

Ingestion of study medication vs placebo

DRUG

Placebo Oral Tablet

Ingestion of study medication vs placebo

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-04-26
Primary Completion
2021-02-26
Completion
2021-02-26
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03714880 on ClinicalTrials.gov